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Background & study aims: Adjuvant endocrine therapy effectively prevents recurrence and progression of
estrogen-receptor positive breast cancer. However, studies reveal substantial non-adherence. The
objective was therefore to identify the nature of the experiences and beliefs of women treated with
endocrine therapy in an attempt to ﬁnd potential determinants of non-adherence.
Method: Online Focus Groups (OFGs) and individual interviews were conducted with 37 women who
were treated with endocrine therapy. Sixty-three statements derived from the OFGs and 11 belief items
from the Beliefs about Medicines Questionnaire (BMQ) were used in a Q-sorting task conducted with 14
of the women. The quantitative Q-sorting data were statistically analyzed with Hierarchical Cluster
Analysis.
Results: A six cluster solution was revealed that included the clusters ‘information’, ‘efﬁcacy’, ‘tenacity’,
‘coping’, ‘side effects’ and ‘usage’. Women’s own experiences and perceptions were not clearly delineated
from the beliefs measured with the BMQ. However, women judged their own experiences and percep-
tions with regard to endocrine therapy as more relevant for adherence than the BMQ beliefs.
Conclusion: In order to understand and to improve women’s adherence to endocrine therapy, women’s
own perceptions and experiences about endocrine therapy should be targeted in addition to common
beliefs that apply to a wide range of medicines.
 2013 Elsevier Ltd. All rights reserved.Introduction
Adjuvant endocrine therapy has improved the prospects of
women with breast cancer markedly. Evidence shows that pro-
longed use of tamoxifen or an aromatase inhibitor strongly reduces
the risk of estrogen-receptor-positive breast cancer recurrence,
disease progression and mortality.1e3 A contradictive ﬁnding is
therefore that adherence to endocrine therapy seems to be almost
as important a problem as it is for such medicines as statins.4
Studies have found substantial non-adherence by the fourth year
of therapy5 and premature discontinuation by 30%e50% of the.
All rights reserved.patients.6,34 Non-adherence to endocrine therapy is a serious
problem that is associated with increased mortality.7
Understanding non-adherence to endocrine therapy is therefore
crucial for clinicians. Clinicians who are aware of the obstacles that
women encounter are better at promoting adherence to endocrine
therapy and in the end women’s health.9 However, understanding
the causes of non-adherence to endocrine therapy is compromised
by a number of factors. First, the causal structure of endocrine
therapy non-adherence is likely to be multifaceted. Over 200 pre-
dictors of adherence to a wide range of medicines have been
postulated.8,9 Which of these factors are especially relevant for
endocrine therapy non-adherence remains unclear. Second, a
comprehensive overview of factors lacks, as different studies have
addressed different factors. Third, many studies focused on beliefs
about medicines. For that goal, the Beliefs about Medicines
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perceived necessities and concerns with regard to medicine use
and the calculation of a difference score thereof called the
necessity-concerns differential.10,11 The BMQ has been used to
explain adherence to various types of medicines.12e18 With regard
to endocrine therapy, non-adherent patients were found to report
beliefs of inefﬁcacy of tamoxifen more often.19 However, as
important as beliefs that apply to a wide range of medicines are
women’s own perceptions and experiences with regard to endo-
crine therapy. Atkins and Fallowﬁeld,22 for example, found that
women who disliked any aspect of their current endocrine therapy
(e.g. side effects and difﬁculties swallowing tablets) were more
likely to be non-adherent. Accordingly, the aim of this study was to
provide a comprehensive overview of women’s beliefs and expe-
riences with regard to endocrine therapy. We examined (a) which
clusters of beliefs and experiences could be identiﬁed, (b) whether
experiences and beliefs regarding endocrine therapy formed
separate clusters and (c) how relevant each cluster of beliefs and
experiences was for therapy adherence.
Patients and methods
Participants
We identiﬁed all breast cancer patients who had been or were
being treated with endocrine therapy at the outpatient oncology
clinic of the Leiden University Medical Center (LUMC), the
Netherlands (n ¼ 175). A total of 54 patients had to be excluded for
the following reasons: metastatic disease, severe or terminal illness
or unclear health status, psychiatric disorders, regimen completion30 patients responded positively
Invitation of 121 patients
Exclusion of patients (n = 54)
- metastatic disease (n = 9)
- severe or terminal illness or health statu
unclear (n = 27)
- psychiatric disorders (n = 2)
- regimen completion > 1 year ago
to avoid recall bias (n = 12)
- language problems (n = 4)
Identification of 175 breast cancer patients (LUM
37 women pa
Leiden University Medical Center (LUMC)
Fig. 1. Flowchart of part>1 year ago to avoid recall bias, and language problems. Therefore,
121 patients were invited to participate of whom 30 patients
responded positively. Another 7 women responded to our call
posted on thewebsite of a patient organization (see Fig.1 Flowchart
of participant recruitment). All 37 participating women returned a
complete informed consent form along with a questionnaire by
means of which we assessed demographic and clinical character-
istics and therapy adherence using the Medication Adherence
Rating Scale (MARS) (R. Horne, M. Hankins, unpublished). The
medical ethical committee approved the study (protocol number
CME10/145). Table 1 shows that there was ample variation in de-
mographic and clinical characteristics of the participants.
Research design
The study consisted of two phases. In Phase I, Online Focus
Groups (OFGs) were conducted to identify women’s beliefs and
experiences with regard to endocrine therapy. In Phase II, following
the methodology by Kool et al.,23 the discussions of these OFGs
were quantiﬁed by means of a Q-sorting task enabling a statistical
analysis of the sorting data.23
Phase I: Online Focus Groups
OFGs24 were conducted by two members of the research team
(LvD and HW) to identify women’s beliefs and experiences with
regard to endocrine therapy (n ¼ 31). Women were individually
interviewed if they did not have internet access (n ¼ 3) or when
they had prematurely discontinued endocrine therapy (n ¼ 3).
Premature discontinuation was deﬁned as discontinuation befores 
7 women responded to our call
on the website
C)
rticipated
Dutch Breast Cancer Patients Society
icipant recruitment.
Table 1
Participants’ demographic and clinical characteristics.
Variables & characteristics Statistic
Demographic characteristics
N 37
Median age (IQ-range*; min & max) 55 (51e62;
31 & 78)
Marital status
Living with a partner (n, %) 26 (70)
Having children (n, %) 24 (65)
Work as main daily activity (n, %) 24 (65)
Educational level
Primary & lower vocational education (n, %) 4 (11)
Secondary & intermediate vocational education (n, %) 15 (41)
Higher vocational education (n, %) 14 (38)
University (n, %) 4 (11)
Endocrine therapy characteristics
Type of endocrine therapy used (n, %)
Tamoxifen 25 (68)
Anastrozole 8 (22)
Letrozole 2 (5)
Exemestane 2 (5)
Median duration of endocrine therapy months (IQ-range) 23 (11e50)
Therapy adherence (n, %) MARS**
Fully adherent: MARS score 25 21 (57)
Partially adherent: MARS score of 24 9 (24)
Nonadherent: MARS score of 23 or < 3 (8)
Discontinuation (n, %)*** 3 (8)
Otherwise 1 (3)
Other clinical characteristics
Median time (months) since diagnosis breast cancer (IQ-range) 28 (19e55)
n lumpectomy vs. n mastectomy (%) 15 (41) vs.
22 (59)
Treated with chemotherapy (n, %) 31 (84)
Treated with radiation therapy (n, %) 23 (62)
Note: *IQ-range, Inter-quartile range; ** Medication Adherence Rating Scale
(MARS); *** Deﬁned as premature discontinuation before the 55th month to allow
for a grace period.
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between the 55the60th month was considered as completion of
the endocrine therapy regimen. Women who had prematurely
discontinued, were interviewed because we deemed it unethical to
bring those women into contact with other women who were still
taking endocrine tablets but who might have had their own doubts
about endocrine therapy.
OFGs were centered on key topics related to endocrine therapy.
Candidate themes for the OFGs were derived from a review of the
general literature and endocrine therapy literature about adher-
ence. These themes were discussed by all authors in multiple
rounds. The following 9 themes were selected: (a) providerepa-
tient relationship,21,25e27 (b) social support,16,21,28,29 (c) medicine
knowledge,30,31 (d) practical aspects of medicine use,19,32,33 (e)
(perceived) medicine efﬁcacy,28,34 (f) (perceived) adverse ef-
fects,19e21,34e36 (g) illness perception,22,26 and (h) coping styles.20,37
An extra theme (i) was added to reﬂect on being diagnosed with
breast cancer and being treated with endocrine therapy (see
Appendix A). Finally, an open theme (j) was posted to verify that in
the discussions about all of the previous themes no important ex-
periences and perceptions had been overlooked. Themes were
posted during a two week period. Every day, except for Saturdays
and Sundays, we posted a new theme on a secured website on
which participants could log on anonymously. Themes remained
posted for the whole two-week period to allow for additional
comments that women had not come up with in the ﬁrst instance.
After posting the theme, participants were sent a reminder by e-
mail to inform them that a new theme had been posted.
Subsequently, based on thorough review by three members of
the research team (HW, LvD, ECGvG), a key list of statements was
extracted from all of the statements made in the OFGs andinterviews. For inclusion in the list, statements (1) were not
allowed to duplicate other statements (2) had not to be vague and
(3) had to be applicable to most women.
Phase II: Q-sorting task
Fourteen women, who participated in the OFGs, also performed
the Q-sorting task. To assure enough variation of opinions, a sample
of ten to twenty participants is recommended for Q-sorting tasks.38
Participants’ median age was 54 years (range 33e63 years). The
median number of months they had been treated with endocrine
therapy was 15 months (range: 1e61 months). In the Q-sorting
task, women were asked to sort the list of key statements printed
on separate cards in two rounds. In the ﬁrst round, lasting 60 min,
women had to form piles from the statements and were asked to
label each pile by a concept that characterized the statements of
that pile.23 In the second round, lasting 30 min, women had to sort
the statements according to the relevance for therapy adherence
into 5 piles (pile 1 least and pile 5 most important). Women were
asked to distribute the statements equally across the 5 piles. Un-
beknownst to the women, the items from the Beliefs about Medi-
cines Questionnaire (BMQ) were added and presented as if they
were statements that had been made by the OFG participants. This
was done to examine to what extent women distinguished com-
mon beliefs that apply to a wide range of medicines from their own
experiences and perceptions regarding endocrine therapy.
Analysis of Q-sorting data
Cluster analysis is a quantitative method to classify related
experiences and beliefs into clusters. Hierarchical Cluster Analysis
(HCA), was used to analyze the piles of statements obtained in
the ﬁrst round of the Q-sorting task. In the data matrix, each
statement was represented by a row. Each column represented a
binary variable that indicated for each statement if it had been put
on a particular pile of a particular woman. In HCA, clusters are
organized hierarchically and can be graphically presented in a tree
diagram. Classiﬁcation (Ward’s method, squared Euclidean dis-
tances) occurs by calculating distances between clusters based on
the number of times statements were put on the same pile. State-
ments with the least distance are classiﬁed in the same cluster. HCA
is hierarchical because at each next higher level, higher-order
clusters are formed of lower-order clusters with the smallest dis-
tance, i.e. lower-order clusters that are most alike. The HCA of the
results from the ﬁrst round of the Q-sorting task was done to
examine which and how many clusters could be formed of beliefs
and experiences with regard to endocrine therapy and whether
beliefs and experiences were clustered separately. The results from
the second round of the Q-sorting task were used to calculate a
median weight that indicated the relevance of each cluster for
perceived therapy adherence.
Results
Phase I: Online Focus Groups (OFGs)
Participants posted 392 reactions in total. The median number
of reactions to the themeswas 39 (minimum 13 toTheme 10: "open
theme", maximum 58 to Theme 2: "perceived support"). Partici-
pants posted a median number of 12 reactions. The total number of
statements extracted from the OFGs was 1188. After excluding
identical statements, ambiguous, irrelevant or vague statements
and statements that were not applicable to most women 141
statements remained. To reduce patient burden, these statements
were further discussed for relevance. While retaining the BMQ
Table 2
Clusters of experiences and beliefs and their relevance for adherence to endocrine
therapy indicated by the weight of the second sorting round. Weights between
parentheses are weights of BMQ* items.
Cluster Weight**
Effect 3.1 (2.6)
Information (foreknowledge, misconceptions, regimen duration) 3.5 (2.9)
Efﬁcacy (hesitation, commitment, dependence) 2.8 (2.2)
Tenacity (deliberation, necessity) 3.8 (e)
Coping (Appreciation, concerns, arduousness, support) 3.1 (2.2)
Side effects (avoidance, inﬂuence exertion, abiding) 2.8 (3.1)
Usage (memory, practicality) 2.6 (e)
Notes: * BMQ, Beliefs about Medicines Questionnaire; ** Median value calculated
from the sortings of the second sorting task i.e. sorting the statements on 5 separate
piles (pile 1: not at all relevant for therapy adherence, pile 5: very relevant for
therapy adherence).
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the OFGs were excluded. The set of statements thus included 74
statements.
Phase II: Q-sorting task round one
Among participants, the number of piles varied from 4 to 12. The
piles received approximately 54 different labels in total. Typical
labels reported by 3 or more participants were background infor-
mation, empathy, side effects, (practical) use, insecurity, efﬁcacy,
and discomfort.
Hierarchical Cluster Analysis (HCA) of the 74 statements sorted
in the ﬁrst round revealed a solution with 6 clusters: ‘information’,
‘efﬁcacy’, ‘tenacity’ ‘coping’, ‘side effects’ and ‘usage’ (see Fig. 2 and
Appendix B).
Information: consisted of the clusters foreknowledge e.g. that side
effects of endocrine therapy were discussed at the start, mis-
conceptions e.g. that it does not matter to take the endocrine tablets
every day at exactly the same time, and regimen duration e.g. that
the duration of therapy was not clear.
Efﬁcacy: consisted of the clusters hesitation e.g. having doubts
about the efﬁcacy, commitment e.g. it is unwise to stop using
endocrine therapy, and dependence such as completion of endo-
crine therapy is an awkward idea.
Tenacity: consisted of the clusters deliberation e.g. using endo-
crine therapy gives the feeling that you try everything to prevent
recurrence of breast cancer and necessity e.g. realizing that endo-
crine therapy is necessary.
Coping: consisted of experiences about support e.g. that people
around you understand it when endocrine therapy causes side ef-
fects, appreciation e.g. it takes time to adjust to endocrine therapy,
concerns e.g. having concerns about harmful effects for the long
term and arduousness e.g. the duration of the endocrine therapy
regimen is long, especially when endocrine therapy bothers you.
Side effects: consisted of the clusters avoidance e.g. you do not try
to think too much about the side effects, inﬂuence exertion e.g. sideForeknowledge (6)
Misconceptions (3)
Regimen duration (2)
Hesitation (5)
Commitment (4)
Dependence (7)
information tenacityefficacy
effect
Deliberation (6)
Necessity (3)
Fig. 2. Tree diagram of experiences and beliefs of womenwith breast cancer regarding their
indicate number of statements.effects are difﬁcult because you cannot control them and abiding
e.g. you try to live with the side effects of endocrine therapy.
Usage: included the clusters of memory e.g. combining endo-
crine therapy use with a daily activity such as putting tablets be-
sides breakfast plate and practicality e.g. taking one tablet per day is
more convenient than taking more than one.
In turn, all of the lower-order clusters except ’usage’ could be
clustered into a higher-order cluster of effect and this higher-order
cluster was linked to the highest-order cluster of experiences and
beliefs. Usage was directly tied to the highest-order cluster of ex-
periences and beliefs.
Phase II: Q-sorting task round two
Table 2 shows the clusters along with their weights assigned
during the second round that reﬂect the importance of each cluster
of beliefs and experiences for perceived therapy adherence. Expe-
riences and beliefs with regard to ‘information’, ‘tenacity’ and
‘coping’ weremost important, whereas those with regard to ‘usage’
were less important.Support (4)
Appreciation (3)
Concerns  (2)
Arduousness (2) 
Avoidance (4)
Influence exertion (5)
Abiding (6)
Memory (7)
Practicality (5)
coping side effects
usage
experiences & beliefs
endocrine therapy. See text for explanation of the labels. Numbers between parentheses
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perceptions and experiences
Turning to the general beliefs that applied to a wide range of
medicines as measured with the Beliefs about Medicines Ques-
tionnaire (BMQ), these appeared not to form a distinct cluster apart
from women’s own experiences and perceptions. Rather, these
were distributed over 4 different clusters namely: ’information’ (1
statement), ’efﬁcacy’ (6 statements), ’coping’ (3 statements) and
’side effects’ (1 statement). The second sorting round, in which
women had to sort the statements for their relevance for therapy
adherence into 5 piles (pile 1 least and pile 5 most important),
revealed that the BMQ statements (Mean 2.6, Standard deviation
0.8) were perceived less important for therapy adherence than
women’s own experiences and perceptions (Mean 3.1 Standard
deviation 0.8) reported during the Online Focus Groups (OFGs):
t(72)¼ 2.08, p¼ 0.04. Across the clusters, the BMQ statements were
considered less important for therapy adherence than women’s
own experiences and perceptions, except for the ‘side effects’
cluster.
Discussion
We identiﬁed the nature and the hierarchical structure of beliefs
and experiences of women with breast cancer regarding endocrine
therapy. Experiences and beliefs pertaining to information and
tenacity seemed to be most important for perceived adherence,
whereas experiences and beliefs related to usage seemed to be less
important for perceived therapy adherence.
Previous studies identiﬁed substantial non-adherence to this
potentially lifesaving medication.5,6,22,27,39 However, predomi-
nantly demographic and clinical predictors of non-adherence were
examined while less studies addressed women’s own perceptions
and experiences. Yet, perceptions and experiences may offer
important clues why and when non-adherence occurs. For clini-
cians, it is therefore imperative to know how breast cancer patients
perceive and experience endocrine therapy in view of the need to
detect the obstacles women encounter when using endocrine
therapy and to support women in adhering and persisting to the
regimen.
To our knowledge this is the ﬁrst in depth study of breast cancer
patients’ perceptions and experiences with regard to adjuvant
endocrine therapy. The clusters we found can be related to previous
ﬁndings. With regard to the lower-order cluster of deliberation
within the ’efﬁcacy’ cluster, Fink et al.40 previously found that
women with negative or neutral beliefs about the value of endo-
crine therapy were more likely to discontinue. With regard to the
lower-order cluster of necessity within the ’tenacity’ cluster,
Grunfeld et al.19 found that non-adherers were more likely to
believe that there was nothing to be gained from taking endocrine
therapy whereas adherers were more likely to believe that endo-
crine therapy would stop them from developing breast cancer.
The most frequently examined experiences in the literature
were side effects6,19,21,27,34 and practical problems.19,22,33 Although
both side effects and practical problems were clusters that we
found, our ﬁndings show that information and tenacity were
perceived more important for non-adherence. Of course, severe
side effects could be important determinants of discontinua-
tion.20,21,34 However, in our opinion, discontinuation because of
side effects would actually reﬂect intolerance rather than adher-
ence behavior. Perhaps women did not consider this as non-
adherence when they were asked to judge each belief and experi-
ence for its relevance to therapy adherence and therefore gave extra
weight to information and tenacity. Future research of this question
is warranted.The importance of information for adherence is consistent with a
previous ﬁnding showing non-adherence to be associated with not
having received information about side effects in advance.21 Another
study showed that apparently ’helpful’ information actually seemed
to increase non-adherence20 perhaps by increasing misconceptions
about endocrine therapy. We found misconceptions to be a lower-
order cluster within the important cluster of information. Regimen
duration was a lower-order cluster within the same cluster of
information, but has received less attention in the literature.
The importance of tenacity is consistent with ﬁndings of a
previously observed pattern of substantially decreasing adherence
in time.5,34 Within the cluster of coping, the lower-order cluster
of support has also received attention in the literature,21 but the
lower-order clusters of appreciation and arduousness have
received less attention. ’Experiences’ and perceptions with regard
to the efﬁcacy of endocrine therapy have received attention too,19
although the lower-order clusters of dependence and hesitation
offer new experiences and perceptions in this regard.
The beliefs applying to a wide range of medicines as measured
with the Beliefs about Medicines Questionnaire (BMQ) were
distributed across various clusters indicating that they could not be
clearly distinguished from women’s own experiences and percep-
tions. However, these BMQ beliefs were perceived less important
than women’s own experiences and perceptions. Also, the BMQ
beliefs about medicines were lacking in the ‘tenacity’ cluster, which
is crucial for long term adherence to endocrine therapy.38
This study had strengths and limitations. A strength of this study
was the combination of in depth Online Focus Groups, with a
conceptual interpretation of the qualitative ﬁndings by the women
themselves using a Q-sorting task and subsequently a quantitative
Hierarchical Cluster Analysis of the Q-sorting data. A sufﬁciently
large number of women from various demographic backgrounds
and with various clinical characteristics participated actively.
Another strength was the discussion of a large number of themes.
There were also limitations. First, in our sample non-adherence
to endocrine therapy was not as pronounced as reported previ-
ously. Perhaps, because this was truly the case. Alternatively, this
may be due to selection bias with non-adherent women being less
willing to participate. Second, to avoid test burden in the interest of
the women, the number of statements had to be limited. Perhaps
this could have resulted in selection bias. However, we tried to keep
bias at a minimum by adopting inter-subjective rules for the se-
lection of statements such as removing identical, vague, irrelevant
or ambiguous statements and thorough discussion of the selection
of statements. Also, none of the women who participated in the Q-
sorting task reported omission of important experiences and
perceptions.Conclusion
Although women’s own experiences and perceptions are not
independent from common beliefs about medicines, they were
regarded as more important for therapy adherence by women
themselves. Consequently, women’s own experiences and per-
ceptions have additional value. For the sake of adherence,
persistence and women’s health, these should be targeted
rigorously.Ethical approval
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